Navigation Links
Arpida Announces Conference Call on 17 April
Date:4/15/2008

mpleted. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may resul
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... 19, 2011 Advances that CSL Behring is ... therapeutic needs of patients with hemophilia A and B will ... medical congress on May 22, 2011. CSL Behring is a ... is a subsidiary of CSL Limited (ASX:CSL). ...
... May 19, 2011 Advantagene, Inc., a Massachusetts-based biopharmaceutical ... the U.S. Food and Drug Administration on a Special ... trial of ProstAtak™, its lead agent for patients with ... accrue 711 patients starting mid-2011 with definitive results expected ...
... 19, 2011 Reportlinker.com announces that a ... its catalogue: Global Biosimilars ... This report analyzes the worldwide ... report provides separate comprehensive analytics for US, ...
Cached Biology Technology:Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference 2Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference 3Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence 2Global Biosimilars Industry 2Global Biosimilars Industry 3Global Biosimilars Industry 4Global Biosimilars Industry 5Global Biosimilars Industry 6Global Biosimilars Industry 7Global Biosimilars Industry 8Global Biosimilars Industry 9Global Biosimilars Industry 10
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... calories leads to a longer life, scientists have proved. ... time that such a diet also can maintain physical ... to physical disability and loss of independence. The study, ... that the diet reduces the amount of visceral fat, ...
... to their social behavior, people sometimes act like monkeys, ... monkey that shares with humans strong tendencies for nepotism ... an expert on primate behavior and an Associate Professor ... University of Chicago. After humans, rhesus macaques are ...
... at Case Western Reserve Universitys School of Medicine ... remarkable discovery with a natural product derived from ... a broad set of applications in various joint, ... bowel syndrome., The publication revealed that Progrado, an ...
Cached Biology News:Severely restricted diet linked to physical fitness into old age 2Humans and monkeys share Machiavellian intelligence 2Humans and monkeys share Machiavellian intelligence 3Natural product discovery by Cleveland medical researchers blocks tissue destruction 2
... Cleland’s Reagent, Immobilized White solid. ... form of DTT on polyacrylamide resin with applications ... 233153 , 233156 , and ... no soluble components are added to the system. ...
... HVJ (hemagglutinating virus of Japan, also named ... tool for transfection of molecules by means ... for siRNA (RNAi), Protein, Oligo, cDNA, Antibodies, ... in vivo. GenomONE-Neo EX has a high ...
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes as ... "driven" to completion. A protective agent for SH ... many other preparations. Blocks the lethal and hypnotic ... Contaminants: Heavy metals: ≤1 ppm. ...
... sequencing of Salmonella genomes has allowed the ... PCR* primer pairs. The S. enterica Typhimurium ... chromosome (4,857,432 bp; 4,440 ORFs) and a ... ORFmers from Sigma-Genosys have been designed to ...
Biology Products: